Last Thursday, September 6,
we sold IBB for a 7 - point gain when it hit our original price target of $ 140.80.
Not exact matches
At the opening bell of last Friday's session, we
sold our position in iShares Nasdaq Biotech ($
IBB) for a modest gain.
The sustained
sell - off lead to the entire cohort to
sell off from all - time highs of $ 132 to $ 83 or 37 % in only 6 months as measured via the iShares Nasdaq Biotechnology ETF (
IBB).